Antisense oligonucleotides (ASOs) are modified single-stranded DNA molecules used in the regulation of unsuitable expression of genes in pathological situations by the specific inhibition of expression of their mRNA targets. ASOs are used for the treatment of spinal muscular atrophy, Duchenne muscular dystrophy, and other genetic disorders.
Market Dynamics
High prevalence of cancer is expected to propel growth of the antisense oligonucleotides market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.
Increasing investment in R&D of cancer is expected to offer lucrative growth opportunities for players in antisense oligonucleotides market. For instance, according to the National Cancer Research Institute (NCRI), cancer research funding by NCRI partners reached around US$ 750 million in 2018/19. Moreover, high prevalence of genetic disorders is also expected to aid in growth of the market. For instance, according to the study, ‘Carrier frequency of SMN1-related spinal muscular atrophy in north Indian population: The need for population based screening program’ published in American Journal of Medical Genetics in October 2020, the carrier frequency of Spinal Muscular Atrophy (SMN)1 deletion was 1 in 38 (16 out of 606).
Absence of large clinical trials confirming the promising results obtained with antisense oligonucleotides in preclinical models is expected to hinder growth of the antisense oligonucleotides market.
Competitive Analysis
Major players in operating in the antisense oligonucleotides market include, Ionis Pharmaceuticals Inc., Aligos Therapeutics, Inc., Sarepta Therapeutics Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Antisense Therapeutics Ltd., Isarna Therapeutics GmbH, Arrowhead Pharmaceuticals Inc., Atlantic pharmaceuticals Inc., Enzon Pharmaceuticals Inc., Bio-Path Holdings Inc., Glaxo smith Kline Plc., Gene Signal International SA., Geron Corporation, Gradlis Inc., ICO Therapeutics Inc., Aptose Biosciences Inc., Marina Biotech Inc., miRagen Therapeutics Inc., Synlogic Inc., OncoGenex Pharmaceuticals Inc., Pharmaxis Ltd., Rexahn Pharmaceuticals Inc., Regulus Therapeutics Inc., and Rxi Pharmaceuticals Inc.
Major players in operating in the antisense oligonucleotides market are focused on adopting partnership strategies to enhance their market share. For instance, in December 2020, Aligos Therapeutics, Inc. entered into an Exclusive License and Research Collaboration Agreement with Merck, under which Merck and Aligos will apply Aligos’ oligonucleotide platform technology to discover, research, optimize and develop oligonucleotides directed against a non-alcoholic steatohepatitis (NASH) target and up to one additional target of interest in the cardiometabolic/fibrosis space.
In-depth Report on Antisense Oligonucleotides Market by Coherent Market Insights:
https://www.coherentmarketinsights.com/ongoing-insight/antisense-oligonucleotides-market-1879
No comments:
Post a Comment